Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17416712 | 0.89 | L3MBTL1 (0.50) | QPCTGAAL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL14701138 | 0.86 | L3MBTL1 (0.46) | QPCTGAAL3MBTL1MEN1KMT2A | |
| SCHEMBL20261998 | 0.83 | TBXAS1 (0.44) | L3MBTL1SMN1; SMN2LMNAPKMTSHR | |
| SCHEMBL28530720 | 0.80 | SMN1; SMN2 (0.64) | QPCTGAAL3MBTL1MEN1KMT2A | |
| SCHEMBL7287782 | 0.78 | SMN1; SMN2 (0.63) | QPCTGAAL3MBTL1MEN1KMT2A | |
| SCHEMBL21998910 | 0.78 | SMN1; SMN2 (0.63) | QPCTGAAL3MBTL1MEN1KMT2A | |
| SCHEMBL21999370 | 0.78 | SMN1; SMN2 (0.63) | QPCTGAAL3MBTL1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL29729358 | 0.77 | SMN1; SMN2 (0.61) | QPCTGAAL3MBTL1MEN1KMT2A | |
| SCHEMBL13472650 | 0.76 | KDM4E (0.67) | QPCTGAAL3MBTL1MEN1KMT2A | |
| SCHEMBL18381194 | 0.74 | TBXAS1 (0.63) | QPCTL3MBTL1SMN1; SMN2LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9217041-B2 | Antibodies that inhibit metalloproteins | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-12-22 | — | — | US | disclosed |
| US-20140141014-A1 | ANTIBODIES THAT INHIBIT METALLOPROTEINS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-05-22 | — | — | US | disclosed |
| US-8697078-B2 | Antibodies that inhibit metalloproteins | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-04-15 | — | — | US | disclosed |
| US-20130209491-A1 | METHODS OF GENERATING ANTIBODIES TO METALLOENZYMES | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2013-08-15 | — | — | US | disclosed |
| US-20130039922-A1 | ANTIBODIES THAT INHIBIT METALLOPROTEINS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130209491-A1 | METHODS OF GENERATING ANTIBODIES TO METALLOENZYMES | ME1, SOD1, MPO | QPCT 2784/4885GAA 129/4885L3MBTL1 2269/4885 |
| US-20140141014-A1 | ANTIBODIES THAT INHIBIT METALLOPROTEINS | NOS2, NOS3, NOS1 | QPCT 2191/4885GAA 1773/4885L3MBTL1 1461/4885 |
| US-20130039922-A1 | ANTIBODIES THAT INHIBIT METALLOPROTEINS | MMP12, MMP1, MMP8 | QPCT 3737/4885GAA 1681/4885L3MBTL1 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.